Understanding Ozempic and Gastroparesis: What Does the Research Show?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Targeted Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. This condition, where the stomach empties slowly, has been a recognized complication in diabetes management for decades, and recent FDA label updates now explicitly acknowledge the link with GLP-1 receptor agonists like Ozempic. This page reviews the current research, FDA warnings, and what patients should know about monitoring and reporting symptoms. The concern is discussed within a growing body of medical literature and safety monitoring.

Ozempic and Gastrointestinal Adverse Reactions: Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal (GI) reactions are prominent and have been documented in clinical trials. In a pool of placebo-controlled trials, GI adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to GI adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, GI adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: Mechanism and Diagnosis

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation often includes postprandial fullness and vomiting of undigested food. Diagnosis is typically confirmed through gastric emptying scintigraphy. The mechanistic pathways linking GLP-1 receptor agonists like Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can exacerbate or unmask gastroparesis in susceptible individuals. This pharmacodynamic effect is dose-dependent and may persist with continued use.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly list gastroparesis as a warning or caution. Instead, GI adverse reactions are grouped under "Adverse Reactions," with specific events such as dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Notably, gastroparesis is not listed among these events, which may indicate underreporting or a lack of specific surveillance for this condition in clinical trials.

Settlement Criteria for Ozempic Gastroparesis Lawsuits

For affected patients, settlement-related considerations hinge on several factors. First, the timeline between exposure to Ozempic and documented harm is critical. Patients who developed symptoms of gastroparesis after initiating Ozempic, particularly during dose escalation when GI adverse reactions are most common, may have a stronger claim. The onset of symptoms such as persistent nausea, vomiting, and early satiety that align with gastroparesis diagnosis should be documented. Second, the adequacy of warnings is central to liability. If the prescribing information did not adequately warn about the risk of gastroparesis, patients may argue that they were not fully informed of potential harms. Third, the severity and duration of harm matter. Gastroparesis can lead to malnutrition, weight loss, hospitalization, and reduced quality of life, which may increase settlement value. Settlement criteria for Ozempic gastroparesis lawsuits typically require evidence of a causal link between the drug and the condition. This includes medical records showing a diagnosis of gastroparesis after starting Ozempic, exclusion of other causes (e.g., diabetes-related autonomic neuropathy, prior surgery, or idiopathic gastroparesis), and a temporal relationship. The dose-response relationship observed in clinical trials, where higher doses of Ozempic were associated with more GI adverse reactions, supports a plausible mechanism. However, individual susceptibility varies, and not all patients will develop gastroparesis. In summary, the evidence from clinical trials indicates that Ozempic is associated with a higher incidence of GI adverse reactions compared to placebo, with dose-dependent effects. While gastroparesis is not explicitly listed in the label, the drug's mechanism of slowing gastric emptying provides a plausible link. Patients considering legal action should consult with a healthcare provider to confirm the diagnosis and with legal counsel to evaluate the strength of their case based on the timeline of exposure, adequacy of warnings, and documented harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect can exacerbate or unmask gastroparesis in susceptible individuals. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, though gastroparesis is not explicitly listed in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require evidence of a causal link: a confirmed gastroparesis diagnosis after starting Ozempic, exclusion of other causes, and a temporal relationship. Key factors include the timeline of exposure (especially during dose escalation), adequacy of warnings, and severity of harm such as malnutrition or hospitalization. Patients should consult both a healthcare provider and legal counsel.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.